COLO B Coloplast A/S Class B

Coloplast SenSura® Mio is Extended Wear in the US

Coloplast SenSura® Mio is Extended Wear in the US

Ostomates now have access to a new option, as a recent patient survey showed that SenSura Mio reduces leakage while matching or outperforming the wear time of other extended wear products1.

Coloplast’s SenSura® Mio ostomy system has been approved in the US for extended wear use, which represents the majority of the US ostomy barrier market2.

“Although the brand was initially launched into the standard wear category, new data shows SenSura Mio is a great option for those seeking an extended wear product,” said Manu Varma, President and SVP of Chronic Care North America.

A recent survey of nearly 2,400 patients demonstrated that SenSura Mio reduces leakage while matching or outperforming the wear time of other extended wear products1. When combined with its full-circle filter, discreet neutral-gray textile, wide outlet, and unique BodyFit Technology, SenSura Mio is now an option for ostomates seeking an extended wear solution that also addresses their concerns around leakage.

Key clinical studies have found:

  • 91% of ostomates worry to some degree about leakage3 
  • 76% of ostomates experienced leakage on some level ranging from a very high degree to a low degree4

A secure fit to the body is important to reducing leakage, and SenSura Mio was designed to fit individual bodies. BodyFit Technology is an elastic adhesive technology that is unique to SenSura® Mio barriers, which adheres securely to the body for protection and provides a flexible fit during movement.

“Patients1, clinicians5, and lab-based data6 confirmed what we have suspected: SenSura Mio performs very well in the extended wear market,” added Varma. “We believe in the strength of our innovative products and are proud more patients in the US now have access to our reliable extended wear solution offered with SenSura Mio.”

is a medical device company that develops products and services designed to make life easier for people with intimate health conditions. Coloplast listens to its users to better understand their needs and responds by bringing the best ideas to market in the form of medical devices and service solutions.

1Ostomy pouch user survey, 2021, n= 2,359. Dataset collected by Coloplast but includes all brands. Data on file.

22017 Medicare data, 3Ostomy Leak Impact tool, 4The Ostomy Life Study: The everyday challenges faced by people living with a stoma in a snapshot, n=4138, June 2015

5Product evaluation of SenSura Mio Convex, 2016, n=98 clinicians.

6Data from bench testing performed by Coloplast. Data on file.



CONTACTS


Peter Mønster

Senior Media Relations Manager, Corporate Communications



Ellen Bjurgert

Vice President, Investor Relations



Attachment



EN
24/08/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

Coloplast AS: 1 director

A director at Coloplast AS bought 2,150 shares at 463.200DKK and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

 PRESS RELEASE

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående p...

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående personers handel med Coloplast-aktier Se venligst vedlagte pdf.   Vedhæftet fil

 PRESS RELEASE

Coloplast A/S - Trading in Coloplast shares by board members, executiv...

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons Please see enclosed pdf.   Attachment

 PRESS RELEASE

Coloplast udnævner Gavin Wood som ny CEO

Coloplast udnævner Gavin Wood som ny CEO Selskabsmeddelelse nr. 3/2026 Intern viden Coloplast udnævner Gavin Wood som ny CEO Det er med glæde, at Coloplasts bestyrelse kan annoncere udnævnelsen af Gavin Wood som ny CEO fra den 1. maj 2026. Gavin Wood afløser Lars Rasmussen, der har været midlertidig CEO siden den 5. maj 2025. Gavin Wood har i to årtier bestredet forskellige ledelsesroller i Johnson & Johnson, senest som øverste leder for Johnson & Johnson MedTech EMEA, en forretning der omsætter for adskillige milliarder dollars og har mere end 7000 medarbejdere på tværs af tre forretnin...

 PRESS RELEASE

Coloplast appoints Gavin Wood as new CEO

Coloplast appoints Gavin Wood as new CEO Announcement no. 3/2026 Inside information Coloplast appoints Gavin Wood as new CEO The Coloplast Board of Directors is pleased to announce the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026. Gavin Wood will take over from interim CEO Lars Rasmussen, who has been in the role since May 5, 2025. Gavin Wood has spent two decades in different leadership roles in Johnson & Johnson, most recently as Company Group Chairman of Johnson & Johnson MedTech EMEA, a multi-billion-do...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch